Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated 2026 milestones across its late-stage rare disease pipeline, including top-line data from the Phase 3 FLASH2 trial of HyBryte™ in early-stage cutaneous T-cell lymphoma expected in the second half of 2026, with an interim analysis approaching in the second quarter and 66 of 80 patients enrolled as of Feb. 10. The letter also reviewed positive Phase 2a data for SGX945 (dusquetide) in Behçet’s Disease published in Rheumatology (Oxford), encouraging Phase 2a psoriasis results for SGX302, ongoing strategic evaluations including partnership and M&A opportunities, and the company’s cash position of approximately $10.5 million as of Sept. 30, 2025, with runway projected through 2026.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer